Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

We are pleased to announce that two trials were recently activated:

Canadian Cancer Trials Group CEC.3 (NCCTG N107C) -- A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease, was centrally activated on September 29, 2011.

Canadian Cancer Trials Group MAC.15 (SWOG S1007) -- A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less, was centrally activated October 5, 2011.

Oncotype DX testing is covered as part of this trial and we anticipate strong accrual as it is the follow-up to the very successful Canadian Cancer Trials Group MAC.12 (ECOG PACCT-1) -- Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial -- wherein Canadian Cancer Trials Group accrued 835 patients.